Vaxxinity Inc (VAXX) AI Stock Analysis

• Market Cap: $2.81M
• Dividend Yield: N/A
• Average Volume (3M): 4.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 65.34
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 126,784,680
• 10 Day Avg. Volume: 12,565
• 30 Day Avg. Volume: 4,501
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 26 Underperform
• Price Target: ―

Vaxxinity Inc's overall score reflects its severe financial difficulties, lack of technical analysis data, and poor valuation metrics. The company's high financial leverage, persistent losses, and cash flow challenges significantly weigh down the score. With no guidance or sentiment from recent earnings calls, there is little to offset these concerns.

Vaxxinity Inc Business Overview & Revenue Model

Company Description

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

How the Company Makes Money

Vaxxinity Inc generates revenue primarily through the development and commercialization of its vaccine candidates. The company aims to advance its pipeline of vaccine products through clinical trials and regulatory approvals, ultimately leading to commercialization. Revenue streams may include licensing agreements, partnerships with pharmaceutical companies, and sales of approved products. Key factors contributing to its earnings include successful clinical trial outcomes, strategic collaborations, and securing funding or grants for research and development. Additionally, Vaxxinity might engage in partnerships with healthcare organizations or governments for the distribution and supply of its vaccines.

Vaxxinity Inc Financial Statement Overview

Summary

Vaxxinity Inc faces significant financial challenges with no revenue growth, high leverage, and negative cash flows. The income statement shows zero revenue and consistent losses, the balance sheet indicates high financial leverage, and the cash flow statement reflects ongoing operational challenges.

Income Statement

Vaxxinity Inc shows a challenging income statement with zero revenue in recent years and consistently negative net income. The company has struggled with profitability, reflected in negative EBIT and EBITDA margins. The lack of revenue growth and continuous losses indicate a need for significant improvement in revenue generation and cost management.

Balance Sheet

The balance sheet of Vaxxinity Inc reveals a high debt-to-equity ratio due to substantial liabilities compared to equity, suggesting high financial leverage. The equity ratio has been weak, reflecting a dependence on debt financing. Despite these weaknesses, the company maintains a decent cash position relative to total assets, providing some liquidity cushion.

Cash Flow

Vaxxinity Inc's cash flow statement shows persistent negative operating and free cash flows, reflecting ongoing operational challenges. The operating cash flow to net income ratio is negative, indicating cash outflows from operations. The negative free cash flow growth rate further highlights financial strain. Despite these issues, the company has managed some positive financing cash flow in prior years.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	66.00K	557.00K	0.00
Gross Profit	-2.23M	-1.68M	-1.87M	505.00K	-107.00K
EBITDA	-56.05K	-74.30M	-135.23M	-31.57M	-13.58M
Net Income	-56.93K	-75.21M	-138.01M	-35.38M	-14.22M
Balance Sheet
Total Assets	44.31M	106.40M	166.67M	50.14M	1.59M
Cash, Cash Equivalents and Short-Term Investments	30.39M	86.83M	144.88M	31.14M	476.00K
Total Debt	15.17M	14.55M	10.70M	38.30M	14.33M
Total Liabilities	30.90M	44.22M	38.05M	137.52M	50.11M
Stockholders Equity	13.41M	62.18M	128.62M	-87.38M	-48.51M
Cash Flow
Free Cash Flow	-58.04M	-57.79M	-82.31M	-35.39M	-12.27M
Operating Cash Flow	-57.24M	-55.93M	-80.99M	-33.91M	-12.27M
Investing Cash Flow	28.84M	-54.39M	-1.32M	-1.48M	0.00
Financing Cash Flow	-1.14M	-167.00K	196.17M	66.11M	11.14M

Vaxxinity Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SCNI	52 Neutral	$1.31M	0.26	138.38%	―	―	―
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
MTNB	45 Neutral	$10.68M	―	-146.46%	―	―	24.30%
APVO	38 Underperform	$6.08M	―	-437.34%	―	―	98.45%
GLTO	29 Underperform	$4.45M	―	-99.96%	―	―	44.00%
VAXX	26 Underperform	$2.81M	―	-0.42%	―	―	―
QNRX	25 Underperform	$4.34M	―	-244.31%	―	―	-146.64%